Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    4.50 (0.90%)
Bid:
505.00
Ask:
505.50
Spread: 0.50 (0.099%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Launch of Share Buyback

20 Jun 2024 07:05

RNS Number : 1334T
Tate & Lyle PLC
20 June 2024
Β 

20 June 2024

Β 

Tate & Lyle PLC

ANNOUNCEMENT OF THE COMMENCEMENT OF A

NON-DISCRETIONARY SHARE BUYBACK PROGRAMME

Tate & Lyle PLC (the "Company") announces that it will shortly commence a share buyback programme (the "Programme") of up to Β£215 million.

On 23 May 2024, the Company announced the intention to return the net cash proceeds from the sale of its remaining interest in Primient to shareholders through an on-market share buyback programme. Previously, this programme was due to start following completion of the Primient sale, but it is now being initiated today.

The Programme, which is non-discretionary, will commence on 20 June 2024 and will end on or before 31 March 2025.

The sole purpose of the Programme is to reduce the Company's share capital.

The Company has entered into an agreement with Merrill Lynch International (the "Broker") to conduct the Programme on its behalf and to make trading decisions under the programme independently of the Company. The Broker will purchase the Company's ordinary shares as principal and sell them on to the Company in accordance with the terms of their engagement. The Company intends to hold the shares it purchases through the programme as treasury shares.

Any purchases of ordinary shares by the Company in relation to this announcement will be made in accordance with certain pre-set parameters set out in the terms of the Broker's engagement, the general authority of the Company to repurchase shares granted by shareholders at the Company's Annual General Meeting held on 27 July 2023 (which permits the Company to purchase no more than 40,165,770 of the Company's ordinary shares).

The LEI reference for Tate & Lyle PLC is 2138008K14474WPKZ244.

End

Β 

For further information please contact:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0)7796 192 688

Β 

Nick Hasell (FTI Consulting), Media Relations

Mobile: +44 (0)7825 523 383

Β 

Β 

About Tate & Lyle:

Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day. Through our expertise in sweetening, fortification, and texture, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

We have more than 3,300 employees working in around 58 locations serving customers across 121 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2024, Tate & Lyle revenue from continuing operations totalled Β£1.65 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on X, Linkedin, Facebook or YouTube.Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
POSGPUGPQUPCGBB
Date   Source Headline
3rd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20263:16 pmRNSForm 8.3 TATE & LYLE PLC
3rd Jun 20262:25 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
3rd Jun 20261:56 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
3rd Jun 20261:56 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20261:40 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 202611:57 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
3rd Jun 202611:15 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:11 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
3rd Jun 202611:02 amRNS20260602_TATE & LYLE_8.5 EPT RI_UK_MLI
3rd Jun 202610:41 amRNSForm 8.3 - Tate & Lyle PLC
3rd Jun 202610:24 amRNSForm 8.5 (EPT/RI)
2nd Jun 20265:13 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
2nd Jun 20265:00 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
2nd Jun 20264:33 pmRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
2nd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
2nd Jun 20263:00 pmRNSForm 8.3 TATE & LYLE PLC
2nd Jun 20262:47 pmRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20262:30 pmRNSAnnual Financial Report and Notice of Meeting 2026
2nd Jun 202612:33 pmRNSForm 8.3 - Tate & Lyle PLC
2nd Jun 202611:47 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:45 amRNS20260601_TATE & LYLE_8.5 EPT RI_UK_MLI
2nd Jun 202611:44 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:32 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
2nd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20268:42 amRNSForm 8.5 (EPT/RI)
1st Jun 20265:27 pmRNS20260526_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:22 pmRNS20260526_TATELYLE8.5 EPT NON-RI BOFASE_replacement
1st Jun 20265:17 pmRNS20260522_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:10 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
1st Jun 20264:55 pmRNS20260521_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20263:35 pmRNSDirector/PDMR Shareholding
1st Jun 20263:30 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 20263:20 pmRNSForm 8.3 TATE & LYLE PLC
1st Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 20262:26 pmPRNInvesco Ltd: Form 8.3 - Tate & Lyle PLC; Public dealing disclosure
1st Jun 20262:17 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 20262:12 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 202611:45 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
1st Jun 202611:37 amRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
1st Jun 202611:24 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
1st Jun 202611:20 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
1st Jun 202611:11 amBUSForm 8.3 - Tate & Lyle PLC
1st Jun 202611:00 amRNSTotal Voting Rights
1st Jun 202610:52 amRNSForm 8.3 – Tate & Lyle plc
1st Jun 202610:49 amRNS20260529_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
1st Jun 202610:47 amRNS20260529_TATE & LYLE_8.5 EPT RI_UK_MLI
1st Jun 202610:29 amRNSForm 8.3 - Tate & Lyle PLC
1st Jun 20268:48 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.